Indeed, as demonstrated by Zhao J. et al. [152], through the secretion of CXCL12, a chemokine that induces the upregulation of FOLR1 in HCC cells, CAFs contribute to resistance to sorafenib therapy. Here, FOLR1 is linked to hepatocellular carcinoma.